CD274 and neoplasm: Patients were initially enrolled regardless of PD-L1 expression, but enrollment was later restricted to patients with ≥5% PD-L1 expression on tumor cells after preliminary data suggested PD-L1 was expressed more commonly on immune cells than tumor cells.